Tirzepatide

Tirzepatide activates both GIP and GLP-1 receptors. It is FDA-approved in the United States under different brand names for type 2 diabetes and for weight-related indications, supported by large randomised trials, and shares the gastrointestinal side effect profile of the incretin class.

Educational content only - not medical advice. In a crisis, call or text 988 (US) or your local emergency number. See crisis resources.